Nanoform Finland has announced the launch of new nanonization technology that is capable of creating biological nanoparticles down to 50 nm. The company said that it has filed for US patents covering the technology and currently has two non-GMP lines capable of producing biological nanoparticles for a proof of concept study.
Nanoform CTO Niklas Sandler said, “We have for several years been developing this new exciting technology for biologics, side by side with our CESS small molecule nanoparticle technology, and it is with great excitement we now start to introduce it to our pharma partners. Potential applications could be in improving delivery route, uptake, and drug loading capacity in formulations and in enabling new drug combinations, tailoring of release profiles, and implementing lighter infrastructure for drug logistics.”
Chief Commercial Officer Christian Jones added, “It is rare for any company to bring to market two groundbreaking platform technologies that could open up significant opportunities for the global pharma industry. I am delighted we are introducing this early development nanoparticle technology in the field of biologics as there are so many areas where nanoparticles can add value in this hugely promising but significantly challenging space. We look forward to exploring the potential advantages with our Pharma and Biotech partners in the hope we can together make better medicines for patients.”
Read the Nanoform press release.
